Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirus–Associated Oropharyngeal Cancer

Morris, Luc G.T.; Sikora, Andrew G.; Patel, Snehal G.; Hayes, Richard B.; Ganly, Ian

doi:10.1200/jco.2010.31.8311

Cited by 309 publications

(316 citation statements)

References 38 publications

Supporting

Mentioning

301

Contrasting

Unclassified

Order By: Relevance

“…[32,33] According to the literature, the incidence of second primary malignancy in larynx cancers ranges between 11-29%. [34][35][36] In a populationbased study performed between 1986-2008, Liao et al determined that 9,996 patients out of 93,891 patients with head neck cancer (11%) had second primary malignancies.…”

Section: Discussionmentioning

confidence: 99%

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Yücel¹

2013

J Med Updates

View full text Add to dashboard Cite

ÖzetAmaç: Bu çal›flmada, klini¤imizde tedavi edilen larinks kanserli hastalar›n tedavi sonuçlar›, tedavilerin yan etkileri ve hastalar›n sa¤kal›-m›n› etkileyen prognostik faktörlerin belirlenmesi amaçlanm›flt›r.Yöntem: Çal›flmada 90 hasta verisi analiz edilmifltir. Hastalar›n performans statüsü 2010'da revize edilmifl Do¤u Onkoloji ‹flbirli¤i Grubu (Eastern Cooperative Oncology Group, ECOG) skorlama sistemine göre de¤erlendirilmifltir. Bulgular:Hastalar›n %97'si erkek ve %3'ü kad›n olup, medyan yafl› 59 (37-86) idi. Erken evre %43, lokal ileri evre %55, metastatik evre kanser %2 hastada saptand›. Hastalar›n %53'ünü glottik kanserler, %47'sini supraglottik kanserler oluflturmaktayd›. Supraglottik kanserlerin performans durumu (p=0.022), grade (p=0.033), T evresi (p=0.034), lenf nod metastaz› (p=0.001), hastal›k evresi (p=0.007) bak›m›ndan glottik kanserlere göre daha kötü özelliklere sahip oldu¤u saptand›. Medyan 15 (da¤›l›m: 5-96) ayda hastalar›n %17'sinde nüks, medyan 17 (da¤›l›m: 1-155) ayda da hastalar›n %12'sinde uzak metastaz tespit edildi. Hastalar›n sa¤kal›m›n› komorbidite (p=0.032), performans durumu (p=0.022), hemoglobin düzeyi (p=0.003), T evresi (p=0.006), hastal›k evresi (p=0.011), kilo kayb› (p=0.002) etkilemekteydi. Kemoradyoterapi uygulanan hastalarda mukozit (p<0.001), bulant› kusma (p<0.001), kilo kayb› (p=0.005), nötropeni (p=0.001) ve anemi (p=0.003), radyoterapi uygulanan hastalara göre daha fazla gözlenmifltir.Sonuç: Hemoglobin düzeyi, T evresi, komorbidite ve kilo kayb› bu hastalar için ba¤›ms›z prognostik faktörler olmufltur.Anahtar sözcükler: Larinks kanseri, sa¤kal›m, prognoz, yan etki. AbstractObjective: Our aim was to determine the treatment results, side effects and the prognostic factors affecting survival in patients with larynx cancer treated in our clinic. Methods:Data of a total of 90 patients with larynx carcinoma were included in the study. The patients' performance scores were evaluated according to the Eastern Cooperative Oncology Group (ECOG) system.Results: Eighty-seven (97%) patients were male and three patients (3%) were female. The median age of the patients was 59 (37-86) years. Early-stage, locally advanced stage, and metastatic disease were detected in 43, 55, and 2% of the patients, respectively. Laryngeal cancers were observed in the glottic (53%), and supraglottic (47%) regions. Performance score (p=0.022), grade (p=0.033), lymph node metastasis (p=0.001), T stage (p=0.034) and disease stage (p=0.007) were significantly unfavourable in supraglottic cancers compared to glottic cancers. Recurrence was observed in 17% of the patients in a median 15 (range: 5-96) months. Distant metastasis was observed in 12% of the patients in a median 17 (range: 1-155) months. The factors affecting survival were the presence of comorbidities (p=0.032), performance status (p=0.022), hemoglobin level (p=0.003), T stage (p=0.006), disease stage (p=0.011), and weight loss (p=0.002). When RT-and CRT-associated side effects were compared, the incidence of adverse effects such as mucositis ...

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Yücel¹

2013

J Med Updates

View full text Add to dashboard Cite

show abstract

“…17 However, other authors reported a lower risk of SPT in HPV-positive oropharyngeal SCC, emphasizing that this fact may be a major contributor to the demonstrated superior survival outcomes among patients with HPV-positive disease. 18 The presence of HPV was detected in the esophageal mucosa of our patient, but the oral lesion was HPV-negative. As the development of SCC remains not totally understood, mainly in patients that lack the habit of tobacco and alcohol, modern molecular techniques may elucidate overall understanding of the biology of these tumors and ways to devise therapeutic strategies to best manage these lesions and improve prospects for survival.…”

Section: Discussionmentioning

confidence: 52%

Multiple Second Primary Oral Squamous Cell Carcinomas in a Nonsmoker and Nondrinker Woman: Case Report and Review of the Literature

Lopes

Aquino

Morais

et al. 2015

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

Aim: This manuscript aims to describe an unusual case of multiple second primary squamous cell carcinomas (SCCs) in several sites of the oral mucosa in a nonsmoker and nondrinker woman and to discuss the diagnostic criteria, clinicopathological aspects and outcome of second primary tumor (SPT). Background:Patients treated for SCC of the head and neck are at high risk for developing SPT arising from the same dysplastic mucosal field. Currently, there is no reliable method to predict which of the patients will develop SPT. Case description:A 64-year-old nonsmoker and nondrinker woman developed several second primary oral SCCs in 7 years of follow-up, most of them being synchronic, treated by surgery without and with chemotherapy and radiotherapy. Conclusion:Patients treated for SCC require a long-term and careful follow-up as the development of SPT contributes with significantly negative impact on the prognosis.Clinical significance: This report describes the diagnosis and management of a very unusual case of several SPTs affecting different sites of the oral mucosa in the same patient. Moreover, the patient had no apparent risk factors associated

show abstract

“…Successful re-challenge of bevacizumab has also been reported but should be done under close supervision, and appropriate BP control should be ensured [20]. The median time to recovery of the neurological symptoms is 7.5 days [21].…”

Section: Discussionmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer

Hamid

Ghani

Micaily

et al. 2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI. Most common precipitants of PRES are acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy, and chemotherapy. Bevacizumab is a monoclonal antibody that halts angiogenesis by inhibiting vascular endothelial growth factor. It has gained widespread popularity in oncology world especially for metastatic and recurrent cancers due to its inherent ability to stop angiogenesis; a vital step for tumor growth. Bevacizumab has also been implicated as the cause of PRES due to dysregulation of the blood-brain barrier. We are reporting a case of PRES induced by Bevacizumab in a patient of colorectal cancer.

show abstract

Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirus–Associated Oropharyngeal Cancer

Cited by 309 publications

References 38 publications

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Multiple Second Primary Oral Squamous Cell Carcinomas in a Nonsmoker and Nondrinker Woman: Case Report and Review of the Literature

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer

Contact Info

Product

Resources

About